

cladribine 2mg/ml solution for injection (LITAK®)

(No: 537/09)

LIPOMED GmbH

Product Update

06 February 2009

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

cladribine (Litak®) is accepted for use in NHS Scotland for the treatment of hairy cell leukaemia.

In patients for whom cladribine is an appropriate agent for this indication, the 2mg/ml solution allows administration by subcutaneous bolus injection over five consecutive days rather than by continuous intravenous infusion of the existing 1mg/ml solution for seven consecutive days. This may confer advantages in terms of convenience to patients and service delivery at a lower cost per course.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 23 December 2008.

**Chairman
Scottish Medicines Consortium**